Latest from research and the clinic.
New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.
Lu-177 PSMA Therapy Cost in India vs the UAE: Real Pricing and Quality Comparison for GCC Patients
For men with PSMA-positive metastatic castration-resistant prostate cancer in the GCC, India offers Lu-177 PSMA therapy at a fraction of UAE or US private-hospital prices - and at accredited centers, quality is comparable. This guide breaks down real 2025 costs, the patient journey from the Gulf, and how to confirm eligibility before you travel.
Lu-177 DOTATATE vs Somatostatin Analogues for GEP-NETs: When to Switch Therapies and What the Evidence Shows
If your GEP-NET has started growing again on an SSA like octreotide or lanreotide, Lu-177 DOTATATE (PRRT) may be the next step. This article compares the two treatments, reviews what the NETTER-1 and NETTER-2 trials show, and explains the key signals that suggest it may be time to switch.
After Your Lu-177 PSMA Cycles: What to Monitor, When to Decide About Next Steps, and How to Get a Follow-Up Care Plan
After your last Lu-177 PSMA cycle for mCRPC, a new phase begins - one focused on monitoring your response and deciding what comes next. This guide explains which blood tests and scans your team will track, what your PSA results mean, and how to build a clear follow-up care plan.
How Lu-177 PSMA Works: Understanding PSMA Targeting and Theranostics for Metastatic Prostate Cancer
Lu-177 PSMA therapy finds and irradiates prostate cancer cells by locking onto a protein called PSMA that is overexpressed on most prostate cancers. This guide explains how the targeting works, what theranostics means in practice, and what the VISION trial showed about outcomes.
Bone Pain and Lu-177 PSMA: Will It Help Your Pain, When Should You Expect Relief, and What If It Doesn't?
Bone pain from metastatic prostate cancer can be relentless. Research suggests Lu-177 PSMA therapy may help many men - but timing, pain flares, and what to do if relief doesn't come are all worth understanding before treatment starts.
Can You Repeat Lu-177 PSMA Therapy: Retreatment Eligibility After Your First Course Ends
A first course of Lu-177 PSMA therapy ends after up to six cycles - but for some men with mCRPC, a second course may be possible. Here is what the evidence shows about retreatment eligibility and what your care team will check before a rechallenge.
Lu-177 PSMA vs External-Beam Radiotherapy for Bone Metastases in mCRPC: How to Decide Which Treatment Is Right for You
Both Lu-177 PSMA therapy and external-beam radiotherapy use radiation to fight bone metastases in mCRPC, but they work in very different ways. Understanding the difference helps you ask better questions and build a clearer plan with your oncology team.
Can You Work During Lu-177 PSMA Therapy? A Practical Guide to Energy, Side Effects, and Returning to Your Job
Fatigue, dry mouth, and radiation safety rules all affect your ability to work during Lu-177 PSMA therapy for mCRPC. This cycle-by-cycle guide helps you plan around treatment and stay in work where possible.
Lu-177 DOTATATE (PRRT) Cost in India vs the US, UAE, and UK: Real Pricing and Quality Comparison for International NET Patients
If you have a neuroendocrine tumor and PRRT is on the table, cost is one of the first real barriers you face. Here is what lutetium Lu-177 dotatate actually costs in India, the US, the UK, and the UAE - and what the quality difference really looks like.
What Your PSA Doubling Time Means for Lu-177 PSMA Eligibility - When to Start Treatment Based on How Fast Your PSA Is Rising
PSA doubling time is one of the key signals oncologists watch when deciding how urgently to discuss the next line of therapy for metastatic castration-resistant prostate cancer. This article explains what your PSADT number actually means, how it relates to Lu-177 PSMA eligibility, and when a fast-rising PSA should prompt a conversation about treatment.
Lu-177 PSMA Therapy Not Available in Your Country? How International Patients Get Treatment in India
Lu-177 PSMA therapy is approved in the US and parts of Europe but unavailable in most other countries. Here is how patients with metastatic castration-resistant prostate cancer from the GCC, Africa, and South Asia are accessing affordable radioligand therapy in India - and what eligibility, cost, and the patient journey actually look like.
My Oncologist Never Mentioned Lu-177 PSMA - How to Find Out If You Are Eligible and Get a Second Opinion
If your oncologist has never brought up Lu-177 PSMA therapy, you are not alone. This guide explains who may qualify for this approved radioligand treatment for mCRPC and how to get a second opinion from a specialist who knows it well.
How we choose what to write about
We focus on three kinds of content:
- Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
- Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
- India updates - new centers, new approvals, new policies that affect Indian and India-bound patients
Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.
Have a specific question about your situation?
A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.
Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.